ClinicalTrials.gg
Not yet recruitingNCT07927322Updated Nov 10, 2026

Patient-Reported and Functional Outcomes After Nonoperative Management of Minimally Displaced Femoral Neck Fractures

An observational study in Femoral Neck Fractures, sponsored by Stanford University. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Stanford University · Observational

Updated Nov 10, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
65 Years and older
Sex
All
01

Study summary

The goal of this observational study is to understand how hip function changes over 24 months in adults with minimally displaced femoral neck fractures who are treated without surgery. The study will also describe outcomes for patients who receive surgery as part of their usual clinical care.

Participants will:

  • Receive treatment chosen through shared decision-making with their orthopaedic surgeon; the study will not change their clinical care.
  • Complete questionnaires about hip function, pain, quality of life, mobility, and daily activities.
02

Conditions studied

  • Femoral Neck Fractures
03

In context

Femoral Neck Fractures

207 studies on the registry are indexed under Femoral Neck Fractures; 40 are open to participants now.

This study's planned enrollment of 100 is below the median of 137 across 60 observational studies indexed under Femoral Neck Fractures.

Browse Femoral Neck Fractures studies →

Lead sponsor

Stanford University is the lead sponsor of 2,168 studies on the registry; 431 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients presenting to Stanford Health Care Emergency Department or Orthopaedic Trauma Clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute minimally displaced femoral neck fracture, valgus-impacted or nondisplaced
  • AO/OTA 31-B1 fracture pattern
  • Presentation within 7 days of injury

Exclusion criteria

Exclusion Criteria:

  • Displaced femoral neck fracture
  • Pathologic fracture
  • Periprosthetic fracture
  • Open fracture
  • Previous ipsilateral femoral neck fracture
  • Previous isilateral hip arthroplasty
  • Polytrauma
  • Delayed presentation to ED
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • Non-operative management group

    Participants treated non-operatively for femoral neck fractures

    Other: Non-operative management

  • Operative management group

    Participants treated operatively for femoral neck fractures

    Procedure: Operative management

Interventions

  • OtherNon-operative management

    Patient reported outcome measures and functional outcomes at 6 weeks, 4 months, 12 months and 24 months post injury

  • ProcedureOperative management

    Patient reported outcomes and functional outcomes at 6 weeks, 4 months, 12 months, and 24 months post injury

06

What researchers measure

Primary outcomes

  1. Changes in Modified Harris Hip Score

    Changes from baseline to 12 months. The modified Harris Hip Score (mHHS) is a measure of physical function scored from 0 to 100, where higher scores indicate better physical function and lower scores indicate worse physical function.

    Time frame: 6 weeks, 4 months, 12 months post injury

Secondary outcomes

  1. Failure of non-operative management

    Failure rate of non-operative management defined as conversion to hemiarthroplasty, or total hip arthroplasty.

    Time frame: 6 weeks, 4 months, 12 months, 24 months post injury

  2. Changes in Oxford Hip Score

    Changes from baseline to 24 months. The Oxford Hip Score is a measure of physical function scored on the 0 to 48 scale. Each of the 12 items scored 0 to 4, higher scores indicating better physical function and lower scores indicate worse physical function.

    Time frame: 6 weeks, 4 months, 12 months, 24 months post injury

  3. Changes in health related quality of life

    Changes from baseline to 24 months in EQ-5D-5L. EQ-5D-5L is a patient reported outcome measure to measure health related quality of life scored on a 5 to 25 scale where higher scores indicate worse health status and lower scores indicates better health status.

    Time frame: 6 weeks, 4 months, 12 months, 24 months post injury

  4. Changes to Barthel Index

    Changes from baseline to 24 months. The Barthel index is a measure of a participant's level of functional independence in basic activities of daily living. It is scored on a 0-100 scale, where higher score indicating higher level of independence and lower score indicating higher level of dependence.

    Time frame: 6 weeks, 4 months, 12 months, 24 months post injury

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 20 observational studies under Femoral Neck Fractures, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 120. This study's planned 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2026
First posted
Nov 10, 2026
StartEst.
Nov 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07927322
Responsible party
Henry Goodnough (Assistant Professor, Stanford University) — Principal investigator
First posted
Nov 10, 2026
Start date
Nov 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion